Neal D. Shore, MD, FACS, presented “GRU Challenging Case: Androgen Deprivation Therapy” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.

How to cite: Shore, Neal D. “GRU Challenging Case: Androgen Deprivation Therapy” January 23rd, 2020. Accessed Jul 2024.

GRU Challenging Case: Androgen Deprivation Therapy – Summary:

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and Atlantic Urology Clinics, leads a panel discussion the physiological and economic factors impacting the ADT selection process. Along with panelists Raoul Concepcion, MD, Michael Cookson, MD, Lawrence Karsh, MD, and Thomas Keane, MD, Dr. Shore emphasizes the impact of the current volume-based and economically incentivized model of treatment and how this can restrict urologists in terms of ADT options. They also discuss the physiological impacts of drug-drug interactions, alternate modes of administration, and the complex prospect of an oral alternative.

About The 30th Annual International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Shore led this panel  during the 30th iteration of the meeting in January 2020.

For further educational activities from this conference, visit our collection page.


Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center and is the Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare, US.

Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored or coauthored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy for the Large Urology Group Practice Association (LUGPA) Specialty Network. He also co-chairs the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology, and he also serves as an editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.